Date: 2017-04-27
Type of information: Licensing agreement
Compound: small molecule inhibitors of an undisclosed cancer metabolism target
Company: Agios Pharmaceuticals (USA -MA) Aurigene (India)
Therapeutic area: Cancer - Oncology
Type agreement: licensing - research - development - commercialisation
Action mechanism:
Disease:
Details:
- • On April 27, 2017, Agios Pharmaceuticals and Aurigene announced a global license agreement to research, develop and commercialize small molecule inhibitors of an undisclosed cancer metabolism target.
- Under the terms of the agreement, Aurigene will provide Agios exclusive rights to its portfolio of novel small molecules for the undisclosed target. Agios will conduct preclinical studies and, if successful, fund further global research and development, as well as regulatory and commercial activities.
Financial terms:
- Financial terms of the agreement include a $3 million upfront payment and potential future milestone payments of up to $17 million per licensed product if certain development and regulatory milestones are achieved by Agios. Aurigene is also eligible to receive low single-digit royalties on product sales.
Latest news:
Is general: Yes
